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Use of Somatostatin Analog in 
Management of Carcinoid Syndrome 
AARON VINIK and ALl REZA MOATTARI 
Carcinoid tumors are the most frequent gut neuroendocrine tumors accounting for more 
than 50% of  all tumors o f  the gastroenteropancreatic (GEP) axis. These tumors appear to 
derive from a stem cell line capable of  differentiating into a variety of  malignant cells that 
secrete many different peptides and amines. The symptoms of  carcinoid tumors are often 
non-specific, vague abdominal pain that may precede the diagnosis by a median of  9 
years. Carcinoid syndrome occurs in <10% of  patients. We evaluated the effects o f  SMS 
201-995 in 14 such patients, 12 with diarrhea, 8 with flushing, 3 with wheezing, one with 
tricuspid valve incompetence, 6 with facial teleangiectasia, 3 with a pellagra type 
dermatosis and one with myopathy. Diarrhea was abolished or significantly reduced in 
83%, flushing in 100%, wheezing in 100%, and myopathy improved in the one patient. 
Blood serotonin was resistant to change, urine 5HIAA fell in 75%, and most gut 
neuropeptide hormones apart from somatostatin were suppressed. Tumor growth ap- 
peared to be slowed in 2/3 of  cases treated for up to 4 years. The analog o f  somatostatin 
appears to be a useful addition to the therapeutic armamentarium for carcinoid tumors 
and the symptom complex. 
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Carcinoids are the most common gut endocrine 
tumors. They derive from a primitive stem cell and 
are generally found in the gut wall. They frequently 
metastasize to the regional lymph nodes and the 
liver. The likelihood of metastases is related to 
tumor size. If less than 1 cm, the incidence of 
metastases is less than 2% but rises to 100% with 
tumors greater than 2 cm in diameter. The carcinoid 
syndrome occurs in less than 10% of patients with 
tumors, and is especially common in tumors of the 
ileum and jejunum, but also occurs with bronchial, 
ovarian, and other carcinoids (I). 
Of all gastroenteropancreatic (GEP) tumors, car- 
cinoids account for 55%, insulinomas 17%, tumors 
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of unknown types 15%, gastrinomas 9%, vipomas 
2% and the remainder 2%. The incidence of these 
tumors is around 1.5 cases per 100,000 of the 
general population, accounting for 13-34% of all 
tumors of the small bowel and 17-46% of all malig- 
nant tumors of the small bowel (2). 
Although carcinoids are classically tumors of 
enterochromaffin and argentaffin cells of the diges- 
tive tract, the term "carcinoid tumor" can be 
expanded to cover "gut"  tumors of paracrine and 
endocrine-like cells of unknown function (3, 4). It is 
now established that these tumors are of neuroen- 
docrine origin and derive from a primitive stem cell 
that may differentiate into any one of a variety of 
adult endocrine secreting cells: B cell and insulin- 
oma; A cell and glucagonoma; D cell and soma- 
tostatinoma; and the PP cell and PPoma, or cells 
capable of producing ACTH, GHRH, VIP, sub- 
stance P, GRF, calcitonin, and the EC cell with its 
ability to cosecrete amines such as serotonin and 
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Fig 1. The differentiation of gastroenteropancreatic tumors from 
a primitive stem cell. 
the peptide motilin. This proposed evolutionary 
development is outlined in Figure 1. At any one 
point in time these cells may secrete one humor, 
whereas at other times the peptide or amine se- 
creted may differ and yield an entirely different 
clinical syndrome. Indeed, metastases are known to 
secrete hormones that differ from the parent tumor 
and different metastases may secrete different hor- 
mones. 
The natural history of carcinoid tumor growth 
and the resultant symptom complex is illustrated in 
Figure 2. The tumors are slow growing and may be 
present for years without overt symptoms, and thus 
escape attention. In the early stages, vague abdom- 
inal pain goes undiagnosed and is invariably as- 
cribed to "irritable bowel or spastic colon." With 
metastases to the liver, the correct diagnosis is 
generally arrived at with a latency, however, of 
many years. Even then, mistaken identity is not 
uncommon and unless biopsy material is examined 
for the neuronal glycolytic enzyme, neuron-specific 
enolase or, the secretory peptide, chromogranin (5), 
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Fig 2. Natural history of carcinoid. 
tumors may be erroneously labeled as adenocarci- 
nomas with a negative impact upon survival and 
attitudes to management. 
The general prognosis in carcinoid is excellent. 
Based upon a world literature of some 2837 cases 
the median survival for all cases is 82% (6). If, 
however, the tumor is localized, then the five-year 
survival is 94%, decreasing to 64% with regional 
lymph node involvement, and 18% with distant 
metastases. Davis et. al (1) reported a mean sur- 
vival of 38 months from the first episode of flushing 
with 25% living for more than six years. With 
regional lymph node involvement, the figure falls to 
about 14 months (7), and with urinary 5HIAA in 
excess of 150 mg/24 hr or inoperable tumors the 
median survival is only 11 months (6). 
Carcinoid syndrome occurs in less than 10% of 
patients with carcinoid tumors. The principle fea- 
tures of carcinoid syndrome include flushing, 
sweating, wheezing, diarrhea, abdominal pain, car- 
diac fibrosis, and pellagra dermatosis. Diarrhea is 
found in 83% of cases, flushing in 49%, dyspnea in 
20%, and bronchospasm in 6% (8). The relationship 
between diarrhea and flushing is variable. One can 
occur without the other, and there may be no 
temporal relationship between the two. The specific 
etiologic agent(s) for each of the protean manifes- 
tations of the carcinoid tumors is not known. Sero- 
tonin (9, 10), prostaglandins (11), 5-hydroxytrypto- 
phan (12-14), substance P (15, 16), kallikrein (17), 
histamine (18), dopamine (19) and neuropeptide K 
(20) are thought to be involved in the clinical 
manifestations of carcinoid tumors. In addition, 
symptoms may be related to overproduction of 
peptides of the proopiomelanocortin family, beta- 
endorphin and enkephalin. Pancreatic polypeptide 
and motilin levels are often raised (21), which may 
be an important marker of tumor activity and pro- 
vide a means of monitoring tumor growth and 
response to therapy rather than contributing to 
specific symptomatology. 
Feldman and O'Dorisio (22) examined the pro- 
portion of 43 patients with carcinoid with increased 
levels of serotonin and various other vasoactive 
peptides. Serotonin, measured either as its urinary 
excretion, urinary 5HIAA, or whole blood seroto- 
nin, was raised in 84% of patients with carcinoid 
tumors and was within normal limits in patients 
with other tumors and miscellaneous illnesses. Uri- 
nary 5HIAA alone had a 73% sensitivity and 100% 
specificity. Seven of their patients had normal uri- 
nary 5HIAA levels, but other indices of serotonin 
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Fig 3. Blood levels of histamine, substance P, and serotonin in 
relation to an episode of flushing. Note the rise in substance P 
precedes the flush. 
production were elevated. Neurotensin and sub- 
stance P were raised in 43 and 32% of patients and 
had specificity values of 60 and 85%, respectively. 
False positives occurred in 23 and 26% of patients 
with conditions other than carcinoid. Motilin and 
somatostatin were raised in 14 and 50%, respec- 
tively. These humors may, however, have a better 
relationship etiologically with the flushing than ser- 
otonin. Figure 3 illustrates a patient who experi- 
enced a flushing episode while being monitored 
continuously. The flushing episode was preceded 
by a rise in substance P and followed by a rise in 
serotonin and a fall in histamine levels in blood. 
Whether this proves to be universal remains to be 
s e e n .  
Even though these humors may not prove to be 
involved in the flushing or diarrhea, they may prove 
useful as an aid in the localization of ostensibly 
occult carcinoid tumors. We have previously re- 
ported on a patient with a 10-year history of flushing 
initially precipitated by alcohol ingestion and four 
years of watery diarrhea (16). Whole-body venous 
sampling with measurements of plasma serotonin 
erroneously localized the tumor to the neck, for 
which a negative exploration was carried out. How- 
ever, substance P levels correctly localized the 
tumor to the ovary and excision was followed by 
cure. The false localization was presumably due to 
serotonin binding to platelets, rendering it difficult 
to identify gradients in plasma in relation to tumor 
overproduction. 
Patients with carcinoid may suffer as a result of 
the endocrine syndrome and/or tumor growth. Sur- 
gical removal of the primary tumor is the treatment 
of choice for small and localized tumors or allevia- 
tion of any obstructive symptoms, but surgical cure 
of carcinoid is almost impossible in the presence of 
intraabdominal and hepatic metastases. Different 
chemotherapeutic agents (23) and surgery or arte- 
rial embolization (24) have been used with variable 
success, but eventual relapse with increasing re- 
sistance to the drugs is encountered (6). Since 
carcinoid is a slow-growing tumor, even patients 
with extensive metastatic disease can enjoy a 
normal quality of life so long as the endocrine 
syndrome is quiescent. Different chemical agents 
such as methysergide, cyproheptadine, heparin, 
phenothiazines, alpha-adrenergic antagonists, cor- 
ticosteroids, H~ and H2 antihistamine blockers, 
and symptomatic treatment of diarrhea with 
opioids, and codeine have been tried with variable 
results (6). Since somatostatin has very broad 
inhibitory effects, somatostatin-14 has been used 
successfully to suppress diarrhea and flushing in 
patients with carcinoid tumors (25), but its clinical 
use is limited by its short half-life (26), with the 
resulting need for continuous intravenous infu- 
sion. With the advent of the long-acting somato- 
statin analog (SMS 201-995) (27), it has been used 
in the treatment of different neuroendocrine tu- 
mors including carcinoid. We have evaluated the 
effects of SMS 201-995 on clinical, biochemical, 
and tumor growth in 14 patients with carcinoid 
tumors. 
PATIENT SELECTION 
Patients with histologically proven carcinoid tu- 
mors were enrolled in the study. The clinical fea- 
tures of 14 patients with carcinoid tumors are 
shown in Table 1. There were eight males and six 
females with a mean age of 60 (range 46-80 years). 
The time interval from diagnosis to initiation of 
SMS therapy ranged from 2 to 96 months when 
some patients underwent surgery and/or chemo- 
therapy. Of 14 patients, 12 had diarrhea, 8 had 
flushing, 3 wheezing, 1 had tricuspid thickening and 
insufficiency, 6 had teliangiectasia, and 3 had a 
dermatosis. 
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TABLE 1. CLINICAL FEATURES OF PATIENTS WITH CARCINOID TUMORS 
Carcinoid 
symptoms and 
Patients Months signs* 
No. and Age since Other Primary 
initials (yr) Sex diagnosis D F W VL T D symptoms Other signs site 
Distant 
metastases Prior treatments 
1. J.B. 55 M 4 + + Hepatomegaly Ileum Liver 
2. E.P. 59 F 4 + + Abdominal pain Ileum Liver 
Weight loss 
3. C.U. 46 F 10 Abdominal pain Pancreas Liver 
Fatigue 
4.  C . S .  61 M 18 
5. V.C. 63 F 29 
6. V.W. 64 F 15 
+ + + - + - Abdominal pain Ileum Liver 
+ + Pancreas Liver 
7.  E.H. 54 M 84 - + + - + - 
8. R.H. 52 M 36 + • 
9. E.S. 80 F 14 + 
10. L.S. 58 M 96 + - -  + + -  
11. R.B. 54 M 39 + + - - + • 
12. J.W. 57 M 2 + + + - + - 
13. E.B. 64 F 5 + • 
14. B.M. 70 M 96 + + + - 
Abdominal pain Hepatomegaly ? Liver 
Weight loss, 
N/V 
Weight loss Hepatomegaly Ileum Liver 
Weight loss Hepatomegaly Ileum Liver 
Abdominal pain Abdominal mass ? Liver 
Weight loss Hepatomegaly 




Abdominal pain Hepatomegaly Ileum Liver 
Jaundice Splenomegaly 
Weight loss Hepatomegaly Ileum? Liver 
Fatigue 
Abdominal pain Abdominal mass Pancreas? Mesentry & 
Weight loss Chylous ascites Nodes 
Weight loss Hepatomegaly Ileum Liver 
Resection of primary 
and debulkation of 
metastases 
Resection of primary 
Resection of primary 
and debulkation of 
metastases 
Resection of primary 
Intrahepatic FUDR 
Resection of primary 
STZ and 5FU 
5FU 
Resection of primary 
Antihistamine 
Resection of primary 
5FU, Cyproheptadine 
Resection of primary 
Cytoxan, 5FU, STZ 
Resection of primary 
Resection of primary 
and debulkation of 
metastases 
*D: diarrhea, F: flushing, W: wheezing, VL: valvular lesion, T: telangiectasia, D: dermatitis. 
In addition to carcinoid symptoms, seven of the 
patients had abdominal pain, nine weight loss and 
patient l0 had severe proximal muscle weakness. 
All patients except case 13 had evidence of liver 
metastases on CT scan. 
The primary site of the tumor was in the ileum in 
eight patients, in the pancreas in two, and in 4 it was 
not identified. In spite of laparotomy, due to exten- 
sive intraabdominal metastases, the primary site 
was not detected in case 9 and was suspected to be 
in the pancreas in case 13. Cases 6 and 13 did not 
have a laparotomy and the diagnosis was made by 
liver biopsy. Case 13 had a suspicious filling defect 
in the ileum on radiographic studies of the small 
bowel. 
Ten patients had resection of their primary tu- 
mors and debulking of metastases and five patients 
had chemotherapy. 
The biochemical features of our patients are 
shown in Table 2. Mean values for blood serotonin 
before and the last value(s) after SMS therapy are 
given. All of the patients except cases 3 and 14 had 
elevated blood serotonin levels. Case 3 had ele- 
vated ACTH as the only hormonal abnormality. 
She did not have any clinical or biochemical evi- 
dence of Cushing's syndrome. Two had diarrhea 
and the Verner Morrison (WDHAA) syndrome. 
Eight patients had elevated 24-hr urinary 5HIAA. 
Serum gastrin was elevated in two cases without 
evidence of ulcer disease and normal serum B12 
levels. Substance P was elevated in cases 4, 5, and 
8. VIP was raised in cases 5 and 6. Both C-terminal 
and N-terminal PTH were elevated in case 9, which 
in the presence of normal calcium and low vitamin 
D was suggestive of secondary  hyperpara-  
thyroidism. There were no selection criteria as far 
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TABLE 2. BIOCHEMICAL FEATURES OF PATIENTS WITH CARC1NOID TUMORS 
Plasma serotonin Urinary 5HiAA 
(ng/ml) (mg/24 hr) Dates o f  Maximum 
Patients No. Other hormonal SMS SMS dosage 
and initials PreSMS PostSMS PreSMS PostSMS abnormalities treatment (ixg/day) 
1. J.B. 2210 1642 78 NL 12/84 1000 
2. E.P. 1125 2323 NL* NL Gastrin: 670 1/85 600 
3. C.U. 160 129 NL NL ACTH: 2030 4/85 300 
4. C.S. 981 671 43 NL Sub. P: 99 7/85 500 
5. V.C. - -  391 NL NL VIP: 158, SubP: 105 9/85 200 
6. V.W. - -  372 NL NL VIP: 668 9/85 600 
7. E.H. 1264 1278 245 NL 7/86 500 
8. R.H. 3162 2157 118 195 Substance P: 67 8/86 500 
9. E.S. 1246 1083 NL NL PTH: 785, (Ca: 10) 9/86 750 
10. L.S. 2385 2345 112 94 Gastrin: 536 11/86 500 
11. R.B. 1886 1903 394 40 12/86 1000 
12. J.W. 2484 2290 144 127 2/87 750 
13. E.B. 1595 1350 NL NL 3/87 750 
14. B.M. 132 124 49 22 4/87 300 
*NL = normal. 
as symptoms or extent of the disease. After written 
consent, the patients were admitted to the Clinical 
Research Unit of the University of Michigan Hos- 
pital from their initial studies and were then fol- 
lowed in the ambulatory care unit with periodic 
readmission to the Clinical Research Unit for eval- 
uation of progress. 
CLINICAL AND PARACLINICAL EVALUATION 
After a complete history and physical exam, 
blood for electrolytes, renal and liver function tests, 
and complete cell count was drawn. Gastrointesti- 
nal hormones (gastrin, pancreatic polypeptide, va- 
soactive intestinal peptide, substance P, motilin) 
and whole blood serotonin were drawn every 4-6 hr 
for 24 hr via an indwelling catheter before and after 
SMS 201-995 therapy. Gastrointestinal hormones 
were measured by previously described methods 
(21), and whole blood serotonin was done by Smith- 
Kline laboratories by a flurimetric method (28-30). 
Twenty-four-hour urines for 5HIAA (31) were col- 
lected before and 24 hr after SMS therapy. 
Serum prolactin, parathyroid hormone, cortisol, 
and ACTH were also measured. Small bowel per- 
fusion studies (32) were done before and 1 hr after 
100 ~g subcutaneous injection of SMS 201-995 in 
six patients with diarrhea. 
Patients with wheezing had pulmonary function 
tests before and one day after SMS 201-995 (100 ~g 
BID). Patients with extra heart sounds, heart mur- 
murs, or shortness of breath were evaluated by 
M-mode and 2-D echocardiogram for evidence of 
right-sided cardiac lesions. In one patient with an 
elevated ACTH value, metapyrone, low-dose and 
high-dose dexamethasone tests were performed. 
One patient with a severe proximal myopathy had 
an electromyogram done before and after recovery 
of muscle strength after treatment with SMS 201- 
995. 
THERAPY 
SMS 201-995 (Sandoz, East Hanover, New Jer- 
sey) was started in an initial dosage of 100 ~g 
subcutaneously every 12 hr and the dose was grad- 
ually increased to control symptoms and correct 
paraclinical abnormalities. The maximum mainte- 
nance dose that we used was 250 Ixg every 6 hr. 
FOLLOW-UP 
After discharge from the hospital, patients kept a 
diary regarding the frequency and consistency 
(formed, soft, or watery) of their bowel movements 
and also episodes of flushing, which were graded for 
duration, extent and severity: (1) face only, (2) face 
and upper extremities, (3) face and upper extremi- 
ties and a rise in pulse rate and/or a decrease in 
blood pressure, and (4) whole body and a decrease 
in blood pressure. 
The patients were followed in the outpatient 
clinic with regular physical examinations, total 
blood count, serum electrolytes, renal and liver 
functions and measurement of gastrointestinal hor- 
mones and total blood serotonin every six weeks. 
Twenty-four-hour urines for 5HIAA, CT of abdo- 
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TABLE 3. CLINICAL AND BIOCHEMICAL RESPONSES TO SMS 
201-995 THERAPY* 
Urinary Blood 
Case Diarrhea Flushing Wheezing 5HIAA serotonin 
1 R R - R N 
2 R R - - W 
3 . . . . .  
4 R R R R N 
5 R R - - ? 
6 R - - - ? 
7 - R R R N 
8 P R - W P 
9 N - - - N 
10 P - - P N 
11 N R - R N 
12 P P R N N 
13 R - - - N 
14 R R - P - 
*R: response  (more than 75% improvement) ;  P: partial response  
(25-75% improvement) ;  N: no response  (less than  25% improve- 
ment);  W: worsening (more than 125% of  initial values); - ;  No  
symp toms  or normal  values;  ?: Pre-SMS values are not  avail- 
able. 
men, and pulmonary function tests in those with 
wheezing were repeated every three months. 
The patients received supplements of pancreatic 
enzymes whenever steatorrhea was present either 
before SMS therapy or if changes in bowel habit 
developed suggestive of malabsorption after SMS 
therapy. SMS was continued as long as the patients 
wished to receive treatment and had evidence of 
clinical or biochemical improvement. Patients who 
showed no response after six months of treatment 
were referred for consideration of chemotherapy. 
EVALUATION OF RESPONSES TO SMS 201-995 
The clinical and biochemical responses of indi- 
vidual cases are shown in Table 3. The responses to 
therapy were divided into four groups. (1) Respond- 
ers were those with more than 75% improvement, 
ie, a 75% drop in the frequency or intensity of a 
symptom or 75% drop in the level of a biochemical 
marker. (2) Partial responders were those with 25- 
75% improvement. (3) Nonresponders were those 
with less than 25% improvement. (4) Worsening 
TABLE 5. EFFECTS OF SMS 201-995 ON 
GASTROENTEROPANCREATIC HORMONES (pg/ml)* 
Gastrin SRIF VIP hPP Motilin Sub P 
Patient M.T.  
Before t rea tment  
Week  2 
Week 4 
Month  2 
Month  3 
Patient D.B. 
Before t rea tment  
Week  2 
Week 4 
Month  2 
Month  3 
Month  4 t 
Patient J.M. 
Before t rea tment  
Week  2 
Week 4 
Month  2 
Month  3 
Month  4* 
Normal  range 
33 79 <10 139 139 <10 
20 41 <10 87 46 <10 
13 85 <10 50 
20 185 <10 15 17 
10 170 <10  14 
36 73 <10  59 
20 76 <10  
30 <10  100 
25 78 <10 50 108 
46 122 10 33 93 




50 324 25 372 521 <10 
29 < I 0  32 <10 
37 252 21 84 323 <10 
37 330 17 107 412 <10 
19 446 <10 91 412 <10 
13 634 23 102 
<150 <150 <25 <1000 <400 <10 
*SRIF: somatosta t in ;  subP: subs tance  P. 
tSMS,  50 ix#day for two weeks.  
SASA twice daily for two weeks .  
was judged to occur if the clinical and/or biochem- 
ical values increased by more than 25% of their 
initial estimation. The overall responses of the 
patients to SMS 201-995 are shown in Table 4. 
Flushing 
Our patients were a heterogenous group with 
advanced carcinoid tumors refractory to conven- 
tional chemotherapeutic agents, who were tried on 
the somatostatin analog with variable clinical and 
biochemical responses. We have previously shown 
a dramatic response of flushing as a symptom to 
treatment with somatostatin (33). Frohlich and col- 
leagues (34) have also reported on the value of 
native somatostatin given by continuous infusion as 
a means of reversing the pentagastrin-induced 
flushing in carcinoid patients. We, however, were 
unable to show that pentagastrin was a reliable 
means whereby flushing could be provoked in our 
TABLE 4. CLINICAL AND BIOCHEMICAL RESPONSES IN 14 PATIENTS WITH CARCINOID SYNDROME 
Urinary Blood 
Diarrhea Flushing Wheezing 5HIAA serotonin 
Responders  7 (58%) 8 (89%) 3 (100%) 4 (50%) 0 
Partial responders  3 (25%) 1 (11%) 0 2 (25%) 1 (10%) 
Nonresponders  2 (17%) 0 0 1 (12%) 8 (80%) 
Worsening  0 0 0 1 (12%) 1 (10%) 
No. of  patients  
(% of  total patients) 12 (86%) 9 (64%) 3 (22%) 8 (57%) 10 (90%) 
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Rgsponses of Flushing to SMS 
[~ Severity (I-4) 
I Frequency (no/day) 
I Duration (I-5) 
i SMS 2 0 1 9 9 5  ASA 
Basal ~ 2 3 4 
Months 
Fig 4. Responses of flushing to somatostatin analog treatment. 
Frequency is markedly improved as well as intensity, but dura- 
tion is unaffected. 
patients. Kvols et al (35) found that 19 of 24 patients 
with carcinoid tumors had a 50% reduction in 
flushing, three a minor response and in two patients 
the drug failed. Richter et al (36) showed that six of 
eight patients had improved symptoms. Our more 
recent experience is that 90% of our patients pre- 
sented with flushing as their major symptom. In all 
instances, the symptom complex improved with a 
clear decrease in the frequency of symptoms with 
doses of 1-2 ixg/kg/day. In no instance was there 
resistance to the drug, tachyphyllaxis did not occur, 
and withdrawal of the drug or substitution with 
distilled water was always followed by recurrence 
of the symptom complex. In contrast to another 
study (36), relapse of flushing did not occur with 
continued treatment once it was under control. 
However,  in contrast to the reduction in number of 
episodes, the severity decreased only slightly and 
the duration of each episode was essentially un- 
changed (Figure 4). 
In order to determine the mechanism whereby 
flushing was reduced, we admitted patients to the 
Clinical Research Unit and monitored episodes of 
flushing without treatment for a 48-hr period and 







H2O Ns + K + Cl" 
Fig 5. The effects of somatostatin analog treatment on small 
intestinal transport of water and electrolytes in 6 patients with 
secretory diarrhea. 
again after treatment with somatostatin for a further 
48 hr. Blood samples were drawn every 4 hr to 
estimate the levels of vasoactive compounds. Table 
5 shows examples in which almost all the measured 
hormones were suppressed by the administration of 
SMS 201-995, save for endogenous somatostatin 
which paradoxically rose with treatment. This may 
suggest that binding of SMS 201-995 to receptors on 
the tumors and the vascular smooth muscle causes 
displacement of endogenous somatostatin and, 
thus, results in a rise in the circulating level. What 
the consequence of this event is remains to be 
determined. 
The extreme example of flushing is the carcinoid 
crisis with a profound fall in blood pressure. It is 
deemed unwise to submit a patient to anesthesia or 
operation without premedication with a combina- 
tion of adrenergic blocker, steroids, thorazine, and 
aspirin. Kvols et al (37) has presented data on one 
such patient who, soon after induction of anesthe- 
sia, had a fall in blood pressure unresponsive to 
intravenous fluid, calcium, neosynephrine, or epi- 
nephrine administration. Within 1 min of 100 Ixg of 
SMS 201-995 given intravenously, blood pressure 
rose and the patient made an uneventful recovery. 
Thus, while the mechanism of action of SMS 
201-995 and the factors mediating flushing and va- 
TABLE 6. SMS 201-955 EFFECTS ON PULMONARY FUNCTION TESTS IN TWO CARCINO[D PATIENTS WITH WHEEZING* 
FVC FEV-I FEF (25-75%) TLC RV DLCo 
Case Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post 
7(E.H.) 3.86 4.89 2.42 3.45 1.46 2.4 9.31 8.76 5.08 3.75 31.2 34.7 
81% 103% 71% 101% 31% 51% 139% 130% 222% 164% 88% 85% 
12(J.W.) 3.06 4.48 1.04 1.74 0.43 0.63 11.03 9.5 7.55 5.05 25.5 30.3 
59% 87% 29% 48% 9% 13% 149% 128% 298% 200% 67% 79% 
*FVC: force vital capacity; FEV-1: force expiratory volume in one second; FEF: force expiratory flow; TLC: total lung capacity; RV: 
residual volume; DLCo: diffusion capacity; Pre: before SMS 201-995; Post: after SMS 201-995. 
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Fig 6. Urinary 5 hydroxyindoleacetic acid (5HIAA) responses to somatostatin analog in 
individual patients. 
sodilatation are not yet clear, there can be no doubt 
that SMS 201-995 is a potent antidote to the vaso- 
active humors participating in the flush and hypo- 
tension. The drug may prove to be a useful adjunct 
in the preparation of patients for operative proce- 
dures and as a standby for the management of 
carcinoid crises. 
Responses of Diarrhea 
Diarrhea occurred in 86% of our patients and 
responded variably to SMS. The acute effect of 
SMS on water and electrolyte transport in six 
patients with diarrhea is shown in Figure 5. The 
overall pattern changed from a secretory to an 
absorptive state. Acute administration of SMS thus 
normalized the water and electrolyte transport 
across the proximal intestine, as has been shown in 
r -  
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SMS SMS 
Fig 7. Mean -+ SD urinary 5HIAA responses to somatostatin 
analog (SMS). P < 0.05. 
patients with WDHH syndrome (38, 39). The acute 
reduction in electrolyte secretion did not, however, 
predict the long-term response of diarrhea to SMS 
therapy, but this needs to be further examined in a 
larger number of patients. Only 44% of our patients 
with diarrhea had complete remission, a finding that 
differs from the improvement in 19/25 patients re- 
ported by Kvols et al (35). This could be due to the 
fact that diarrhea in patients with carcinoid tumors 
has multiple etiologies, ie, secretory, increased mo- 
tility, malabsorption, partial luminal lymphatic ob- 
struction, bacterial overgrowth, and short bowel 
syndrome due to surgical resection. The diarrhea 
may even appear to worsen with the appearance of 
















Fig 8. Mean - st) serum serotonin values before and after 
treatment with the analog. P = NS. 
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Fig 9. Responses to treatment of a patient with secretory 
diarrhea due to metastatic carcinoid secreting VIP. 
faced with the confounding situation of not knowing 
to what to attribute the symptom. However, al- 
though somatostatin does inhibit exocrine pancre- 
atic secretion (40), addition of pancreatic enzyme 
supplementation has not uniformly decreased SMS- 
induced steatorrhea (41). We did not find any con- 
sistent changes in frequency or consistency of 
bowel movements in response to pancreatic supple- 
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Fig l l .  Malignant carcinoid, failure of response of ACTH to SMS 
despite tumor shrinkage (Fig. 10). 
ment in those patients with steatorrhea before treat- 
ment or in the bowel habits after therapy with SMS 
201-995, compatible with the notion that the stea- 
torrhea has a complex pathogenesis and may be 
contributed to by alterations in bile flow, the direct 
effects of somatostatin on nutrient absorption, and 
intestinal motility (42). 
The significant improvement in water and elec- 
trolyte transport across the small intestine after the 
initial dose of SMS without significant changes in 
blood serotonin implies a direct effect of SMS on 
the target organ independent of serotonin mediation 
(43). 
Effects of SMS on Pulmonary Function 
All three of our patients with wheezing had 
clinical improvement, and spirometric improve- 
22S 
Fig 10. Regression of carcinoid after SMS, July 1985 to January 1987. 
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Fig 12. Progression of carcinoid after SMS, December 1984 to August 1986. 
ment was documented (Table 6). Pulmonary func- 
tion did not improve further after three months of 
treatment, indicating an irreversible component or 
small airway disease secondary to long-standing 
smoking. 
Effects of SMS on Myopathy 
Patient 10 in our series presented with severe 
proximal muscle weakness, with normal muscle 
enzymes and nerve conduction studies but elec- 
tromyographic features of a proximal myopathy. 
Although a neurological deficit secondary to meta- 
static carcinoid has been seen (44), metabolic- 
induced neuromuscular disease is very rare (45- 
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Fig 13. Progressive reduction in blood serotonin levels despite 
progression of tumor growth (Fig. 12). 
kalemia, at the time of admission his potassium 
was normal with no biochemical evidence of thy- 
rotoxicosis, ectopic ACTH production, or osteo- 
malacia. We believe that his severe myopathy was 
due to his carcinoid, although it might have been 
aggravated by severe diarrhea, weight loss, and 
poor nutrition. Histological changes can be in- 
duced in skeletal muscle of mice by intraperitoneal 
injection of 5HT (48). Three months after SMS 
therapy, the patient did not have any clinical 
evidence of myopathy with improvement in elec- 
tromyographic features. 
Biochemical Responses 
There are conflicting reports regarding the bio- 
chemical responses of carcinoid patients to soma- 
tostatin. Richter et al (36) reported a significant 
drop in 5HT in eight patients treated with 150 Ixg/ 
day of SMS 201-995, but no changes in urinary 
5HIAA, while others have found a drop in urinary 
5HIAA (43). In prolonging treatment of four of their 
patients to 15-30 weeks, blood serotonin remained 
unchanged (41). In our patients, urinary 5HIAA 
dropped in almost all patients and normalized in one 
third of the patients. Figure 6 compares the urinary 
5HIAA before SMS therapy with the most recent 
values after therapy. Three of eight patients normal- 
ized their 24-hr 5HIAA. In case 8 urinary 5HIAA 
initially dropped but subsequently rose. The overall 
post-SMS 24-hr urinary 5HIA was significantly 
lower than basal values (P < 0.05) (Figure 7). 
The blood serotonin levels during the course of 
therapy are shown in Figure 8. Although few of our 
patients had a fall in their blood serotonin level, the 
overall post-SMS values were not significantly 
lower than pretreatment values. 
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Fig 14. Lack of progression of carr after SMS, June 1986 to March 1987. 
There was no clinical correlation between clinical 
responses and either the urinary 5HIAA or the 
blood serotonin levels. This may reflect the fact that 
there are multiple etiologic factors involved in the 
symptomology of carcinoid tumors. In our patients, 
those who responded clinically required no more 
than 500 txg/day to control their symptoms, al- 
though we have examined the response to higher 
doses in certain instances. 
Responses of Tumor Growth and Metastases 
Due to the slow growth of carcinoid tumors, it is 
difficult to assess the effect of SMS on the rate of 
tumor growth or regression. Shrinkage of liver 
metastases in patients with carcinoids (35, 39) and 
other functioning pancreatic neuroendocrine tu- 
mors (49) has been reported. We have had variable 
experiences. Patient 6 was seen in 1980 with watery 
diarrhea two to three times per day, vomiting after 
meals, and weighed 140 lb. A diagnosis of spastic 
colon was made. In May 1984, CT showed an 
enlarged liver, which was shown to be an adenocar- 
cinoma on biopsy in January 1985, for which she 
received four months of chemotherapy with 5- 
fluorouracil. After four months she had a perforated 
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Fig 15. Failure of increasing doses of SMS to alter blood serotonin values despite inhibition of tumor 
growth (Fig. 14). 
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metastatic carcinoid tumor. VIP levels postopera- 
tively were found to be in the >1000 pg/ml region 
(normal <150 pg/ml). In September 1985, she was 
seen at the University of Michigan and was found to 
have almost complete replacement of the right lobe 
of the liver with metastases and had lost 45 lb 
weight. Initiation of SMS treatment resulted in 
cessation of diarrhea (Figure 9). Six months later 
she presented with severe right upper quadrant 
pain, CT showed infarction of the tumor, and VIP 
levels had returned to the near normal range. 
The relationship between tumor size and growth 
and the biochemistry is not a simple one. Figure 10 
shows a patient in whom the tumor is clearly 
shrinking, but ACTH levels have risen to the 2000- 
3000 pg/ml range (Figure 11). On molecular sieve 
chromatography, the ACTH coeluted with native 
ACTH but, the patient has no clinical features of 
Cushing's, is gaining weight, and has no diarrhea or 
flushing. Figure 12 illustrates progression of tumor 
growth after 18 months of SMS therapy, yet there 
has been a dramatic fall in blood serotonin values 
(Figure 13), and the patient is entirely asympto- 
matic. Figure 14 illustrates the opposite situation of 
unchanged tumor size, a very well patient and 
hormonal levels that were unaffected by SMS even 
in doses as high as 1000 txg/day (Figure 15). 
We have follow up CT in 10 patients. Cases 4 and 
6 showed some regression of the tumor, in case 6 it 
infarcted. Cases 1,2, 9, and 11 showed progression, 
and cases 3, 5, 7, 8, and 10 showed no changes on 
the CT scan followed for up to two years. Cur- 
rently, we are using higher doses of SMS to see if 
we can suppress all biochemical markers and also 
tumor growth. 
Incidence and Nature of Side Effects 
No major clinical side effects have been observed 
in our patients. Initially, during injection of soma- 
tostatin a few patients experienced a burning sen- 
sation at the site of injection that improved with 
slow injection of the drug. A few patients had 
nausea and/or light-headedness immediately after 
injection lasting up to 30 min that gradually faded 
with repeated injection. We have also had one 
patient present with acute calculous cholecystitis 
after two years of treatment with SMS, but retro- 
spective analysis revealed the presence of gall- 
stones on CT done before the advent of SMS 
treatment. We have also observed that steatorrhea 
seems to occur in a dose-dependent manner. With 
doses greater than 500 Ixg/day, steatorrhea is almost 
Digestive Diseases and Sciences, Vol. 34, No. 3 (March 1989 Supplement) 
universal, but as mentioned above, does in some 
instances respond to pancreatic enzyme supple- 
ments. 
SUMMARY 
We have reviewed the literature on current ther- 
apy of carcinoid patients with special emphasis on 
the use of SMS 20-1995. In addition, we present 
data on the effects of SMS 201-995 on clinical and 
biochemical indices and tumor growth. Diarrhea is 
abolished or significantly reduced in 83% of pa- 
tients, flushing improves in 100%, wheezing im- 
proved in 100% with a decrease in airways resis- 
tance, and in one patient myopathy has improved. 
Blood serotonin is notoriously resistant to inter- 
vention, and urinary 5HIAA will decrease margin- 
ally in 75% of cases. Tumors, in general, continue 
to grow, but this may be slowed or in rare cases 
tumor growth is arrested. In individual instances 
the tumor may even infarct, leading to spontaneous 
cure.  
Short of an effective curative or palliative agent, 
SMS can control flushing and wheezing in most and 
diarrhea in some patients with carcinoid tumors 
with improvement of their general condition. The 
effects of SMS on tumor growth needs to be further 
evaluated in relation to the slow progression and 
indolent nature of these tumors. Since little effec- 
tive therapy is available and much may be harmful, 
it seems not unreasonable to offer SMS 201-995 for 
the control of symptoms and  for palliation at this 
point in time. Limits of safe and effective dosage 
need to be established and long-term follow-up is a 
prerequisite to defining the ultimate role of this form 
of peptide therapy in the carcinoid syndrome. 
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